scholarly journals Prevalence and Associated Factors of Hepatitis B Surface Antigen (HBsAg) among People Living with HIV (PLWHIV) Attending at CTC Mawenzi Regional Hospital Kilimanjaro, Northern Tanzania

2021 ◽  
Vol 11 (02) ◽  
pp. 216-231
Author(s):  
Benedicto Shimula Nyalika
Keyword(s):  
Hepatitis B ◽  
Surface Antigen ◽  
Associated Factors ◽  
Hepatitis B Surface Antigen ◽  
Regional Hospital ◽  
People Living With Hiv ◽  
Northern Tanzania ◽  
Living With Hiv

Incidence and predictors of hepatitis B surface antigen clearance among people living with HIV and hepatitis B

2020 ◽  
Vol 73 ◽  
pp. S591
Author(s):  
Mamta Jain ◽  
Karen Vigil ◽  
Xilong Li ◽  
Paul Parisot ◽  
Gabriella Go ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
People Living With Hiv ◽  
Living With Hiv

scholarly journals Prevalence of hepatitis B and C infection and associated factors in people living with HIV in Midwestern Brazil

2015 ◽  
Vol 19 (4) ◽  
pp. 426-430 ◽  
Author(s):  
Natália Alberto Alves Brandão ◽  
Irmtraut Araci Hoffmann Pfrimer ◽  
Celina Maria Turchi Martelli ◽  
Marília Dalva Turchi
Keyword(s):  
Hepatitis B ◽  
Associated Factors ◽  
People Living With Hiv ◽  
Living With Hiv

scholarly journals Hepatitis B Infection in People Living with HIV/AIDS; A Retrospective Study of the Effia Nkwanta Regional Hospital

2019 ◽  
pp. 1-9
Author(s):  
Richard Anthony ◽  
Ruth C. Brenyah ◽  
Kwame O. Darkwah ◽  
Blessing C. Egbule ◽  
Jerry P. K. Ninnoni ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Highly Active Antiretroviral Therapy ◽  
Laboratory Data ◽  
Regional Hospital ◽  
People Living With Hiv ◽  
Aids Patients ◽  
Cd4 Cell Count ◽  
Total Prevalence ◽  
Living With Hiv ◽  
Hiv Aids

Introduction: Comorbidities among people living with HIV/AIDS (PLWHA) increases with disease severity. This may be attributed to highly active antiretroviral therapy (HAART) toxicity and HIV/AIDS-related infections.   Aim: We investigated the presence of comorbidities among PLWHA and reported their clinical and biochemical characteristics. Methods: This study was conducted at the Effia Nkwanta Regional Hospital (ENRH) in the South-Western part of Ghana. A retrospective data of 500 participants (134 males and 366 females) was collected from HIV/AIDS patients on HAART (January 2012 to January 2016). Sociodemographic characteristics and laboratory data of patients were retrieved from patients’ clinical files and laboratory database respectively. Data was analyzed with SPSS for both descriptive and inferential analysis. Results: A total of 96 (19.2%) comorbidities were recorded (N=500). The most prevalent comorbidity was hepatitis B virus infection (34.4%). Among the 96 HIV/AIDS patients who had comorbidities, 27 (28.1%) were males and 69 (71.9%) were females. The systolic blood pressure (SBP) of the HIV/AIDS patients with comorbidities was similar to that of those without comorbidities (113.84 ± 16.73 vs 115.32 ± 15.68). Majority of the participants with comorbidities 59 (61.5%) and those without comorbidities 227 (56.2%) were found to be on the same therapy combination (TDF+3TC+EFV). The decreased CD4 cell count, estimated glomerular filtration rate (eGFR), serum potassium and creatinine were similar in the participants (those with comorbidities and those without comorbidities). None of the demographic, clinical and biochemical parameters were associated with the presence of comorbidities. Conclusion: The total prevalence of commodities was 19.2% and the most prevalent commodity was HBV (34.4%). The comorbidities were common among females, the married and old people living with HIV/AIDS. Early and regular screening will be a key prevention and control strategy for the HIV/AIDS-associated commodities.

scholarly journals Hepatitis B surface antigen and associated factors among mothers who had antenatal care contact in Attat Hospital, southern Ethiopia

2021 ◽  
Vol 9 ◽  
pp. 205031212110244
Author(s):  
Yohannes Fikadu Geda ◽  
Hailu Desse ◽  
Molalegn Mesele Gesesse ◽  
Tamirat Melis Berhe
Keyword(s):  
Multivariate Analysis ◽  
Hepatitis B ◽  
Confidence Interval ◽  
Antenatal Care ◽  
Surface Antigen ◽  
Odds Ratio ◽  
Associated Factors ◽  
Adjusted Odds Ratio ◽  
Hepatitis B Surface Antigen ◽  
Pregnant Mothers

Introduction: Hepatitis B virus is a viral infection which can cause both acute and chronic liver disease. Predominately, this virus transmitted through the mother-to-child route. It is an endemic disease in low-resource setting countries like Ethiopia. Objective: Therefore, this study was used to assess magnitude and associated factors of hepatitis B surface antigen among pregnant mothers, who had antenatal care in Attat Hospital. Method: The cross-sectional study was conducted from 1 September 2019 to 30 January 2020. The data were collected from serological testing in laboratory and interview in antenatal care on 422 pregnant mothers. The data were entered into Epi Data version 3.1 and exported to SPSS version 24.0 for further analysis. Variables on bivariate analysis at p < 0.25 were taken to multivariate analysis. A p value of less than 0.05 on multivariate analysis was considered significant. Result: From 438 total samples, 422 respondents were participated and the mean age of the participants was 25.4 years (standard deviation ± 4.85). Magnitude of hepatitis B surface antigen was 10.9% (95% confidence interval: 8.3, 14.0). Respondents whose occupation was in government or self-employed were 67% (adjusted odds ratio = 0.33, 95% confidence interval: 0.12, 0.91) and whose number of gravidity was 3 and below were 79% (adjusted odds ratio = 0.21, 95% confidence interval: 0.04, 0.68) less likely to have hepatitis B surface antigen. Respondents who respond that hepatitis B surface antigen has cured were 1.52 times (adjusted odds ratio = 1.52, 95% confidence interval: 1.7, 9.4) more likely to have hepatitis B surface antigen. Respondents who answered hepatitis B surface antigen has vaccine were 57% (adjusted odds ratio = 0.43, 95% confidence interval: 0.05, 0.75) less likely to have hepatitis B surface antigen. Conclusion: Magnitude of hepatitis B surface antigen among mothers who were on antenatal care in Attat Hospital was high compared to other studies. Being employed in government or self-employed, gravida 3 and below, those who think that the disease has vaccine and those who think hepatitis B surface antigen was curable were statistically significant factors. Health promotion should be an important recommendation to be done by the hospital.

scholarly journals Hepatitis B infection in people living with HIV who initiate antiretroviral therapy in Zimbabwe

2020 ◽  
Vol 10 (3) ◽  
pp. 97-103
Author(s):  
T. P. Goverwa-Sibanda ◽  
C. Mupanguri ◽  
C. Timire ◽  
A. D. Harries ◽  
S. Ngwenya ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Hepatitis B ◽  
Opportunistic Infections ◽  
Hepatitis B Surface Antigen ◽  
Prevalence Ratio ◽  
Diagnosis And Treatment ◽  
People Living With Hiv ◽  
First Line ◽  
Cross Sectional ◽  
Living With Hiv

Setting: There is little information about the diagnosis and treatment of hepatitis B virus (HBV) infection in people living with HIV (PLHIV) in Zimbabwe despite recommendations that tenofovir (TDF) + lamivudine (3TC) is the most effective nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) backbone of antiretroviral therapy (ART) in those with dual infection.Objective: To determine 1) numbers screened for hepatitis B surface antigen (HBsAg); 2) numbers diagnosed HBsAg-positive along with baseline characteristics; and 3) NRTI backbones used among PLHIV initiating first-line ART at Mpilo Opportunistic Infections Clinic, Bulawayo, Zimbabwe, between October 2017 and April 2019.Design: This was a cross-sectional study using routinely collected data.Results: Of the 422 PLHIV initiating first-line ART (median age 34 years, IQR 25–43), 361 (85%) were screened for HBV, with 10% being HBsAg-positive. HBsAg positivity was significantly associated with anaemia (adjusted prevalence ratio [aPR] 2.3, 95%CI 1.1–4.7) and elevated ala-nine transaminase levels (aPR 2.9, 95%CI 1.5–5.8). Of 38 PLHIV who were diagnosed HBsAg-positive, 30 (79%) were started on ART based on tenofovir (TDF) and lamivudine (3TC), seven were given abacavir (ABC) + 3TC-based ART and one was given zido vudine (ZDV) + 3TC-based ART.Conclusion: In PLHIV, HBV screening worked well, the prevalence of HIV-HBV co-infection was high and most patients received appropriate treatment for both conditions. Recommendations to improve screening, diagnosis and treatment of HIV-HBV co-infection are discussed.

scholarly journals Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Jean Damascene Makuza ◽  
Jean Olivier Twahirwa Rwema ◽  
Corneille Killy Ntihabose ◽  
Donatha Dushimiyimana ◽  
Justine Umutesi ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Surface Antigen ◽  
Associated Factors ◽  
Hepatitis B Surface Antigen ◽  
Hbsag Positivity

scholarly journals Incidence and predictors of hepatitis B surface antigen clearance in HIV patients: a retrospective multi-site study

2021 ◽  
Author(s):  
Mamta K Jain ◽  
Karen J Vigil ◽  
Paul Parisot ◽  
Gabriella Go ◽  
Trung Vu ◽  
...  
Keyword(s):  
Drug Use ◽  
Hepatitis B ◽  
Injection Drug Use ◽  
Surface Antigen ◽  
Hepatitis B Surface Antigen ◽  
Injection Drug ◽  
People Living With Hiv ◽  
Hiv Patients ◽  
Hbsag Loss ◽  
Hbsag Clearance

Abstract Background New therapies to achieve hepatitis B surface antigen (HBsAg) clearance are under development. However, gaps in knowledge exist in understanding the incidence and predictors of HBsAg clearance in a racially diverse HIV population. Methods We examined the incidence and risk of HBsAg clearance in a retrospective cohort of people living with HIV/HBV. Included patients had sufficient data to establish chronic infection based on CDC guidelines. We examined the incident rate for HBsAg loss and hazard rate ratios to evaluate predictors for HBsAg clearance in a multivariable model. Results Among the 571 HIV/HBV, 87% were male, 61% Black, 45% had AIDS, 48% HBeAg-positive, and median follow-up was 88 months. Incident HBsAg clearance was 1.5 per 100 person-years. In multivariate model, AIDS at baseline [adjusted hazard ratio [(aHR) 2.43, 95% CI:1.37,4.32 ], Hispanics (aHR 3.57, 95% CI: 1.33, 9.58), and those with injection drug use as an HIV risk factor (aHR, 3.35, 95% CI: 1.26, 8.89) were more likely to lose HBsAg whereas those who were HBeAg-positive (aHR 0.34, 0.19, 0.63) were less likely to lose HBsAg. Median change in CD4 cell count during the observation period was 231 cells/mm 3 in those with HBsAg loss vs. 112 cells/mm 3 in those with HBsAg persistence (p=0.004). Conclusion HBsAg loss occurs in about 10% of those with chronic HBV-infection. Hispanics, AIDS at baseline, injection drug use history, and HBeAg-negative status at baseline predicted the likelihood of HBsAg loss. Immune restoration may be a mechanism through which HBsAg loss occurs in HIV patients.

Sign in / Sign up

Export Citation Format

Share Document